Member Info for Peterrr

Nope 1p for the next year, this is a turnaround opportunity and a buy in now may equate to 30% future reurn if all the ducks line up.

My takeaways, no real surprises..

Another chunky tranche of impairments from credit cards going to be realised this year.

Headcount reduction well ahead of target, so cost savings should exceed original plan.

Revenue looks sound

App may be generating noise, buts that's all it generated to year end

Chairman staked 100% of his his salary buying in

CEO does have a chunky performance component but won't be crying poor if he misses out.

Solvency etc all good

160+ pages, anyone else?

It is a discussion board where everyone is entitled to an opinion, even if it is wishful thinking. Take all or part of it or reject it, I don't mind. I'd love your predictions to come true, just think it is probably not yet.

They will not want to go to Nasdac without crystalising the grant shares first They are are not contemplated for a carry over. For a reverse you need a failed Nasdac Co with some cash.so you take control not share it. Cash is needed as intangibles won't cut it for valuing the shares on merger for the 4USD min. The phase 2 cash probably wont be delivered in one chunk so at the moment they need more than I can see coming in to do it.

Costs would have been known pretty close but maybe they were angling for a bigger grant or commercial loan. Anyway I'd take this over a buyback for use of funds, but kitty must be looking a bit slim now.

I'm a little late to the party here Mary only a few days in but I reckon there will be a pump on the next news and it may hit 12 before that.

Actually I didn't look wide enough, Bulgaria is covering Switzerland and it looks like they have opened a second office.

I don't care if the ceo buys shares the performance related package means he will have to deliver or miss out. Plenty of CEOs don't buy because they can't sell until they leave the job. Chair however would need to buy in to get the same upside. CEO delivers and the share price and div is restored. He buys in but fails to deliver it will end up sub 50.

I see a ramp up in the European ops to service expanded offerings to French and German telcos and now insurance clients from the Polish offices. These are profitable contracts in an area where Capita has a good name. Bulgaria service centre doesn't look like it has much traction in comparison.

I'm also not comfortable with the apparent conflict of interest, it would need to be declared at pretty much every board meeting. However I think the core portfolio is generating sufficient momentum and excellent press coverage that at the end of the day there will be enough of the pie to share around so we can all get a feed.

Nice find eirico, but will need to get the share price up unless you are happy with a 40:1 reduction to meet Nasdac minimum. I'm not. I'm not sure it would generate much interest with a couple of phase 1 trials under the belt. Let's bed down the £15+ million needed for the phase 2 and to keep the ship afloat and grow the pipeline for the next couple of years whilst that happens and then if success it will fly.

Thanks Steph and others on this forum for some well reasoned opinions without mud slinging. My own 2 cents on this specifically I would want someone not in client relationship to provide a research note on Molton, so not Eddison.

I'll get more committed when scale up trials are completed successfully and a material supply contract or license is in the bag, without regulator intervention. I see the Australian government requires 5 years of safety trials in bulk with all product destroyed for anything considered GMO in this space. US probably more comfortable with it.

RNS good news and underpins ongoing gov financial support for the tech which minimises dilution. May add a few whilst the price is so miserable.

Des I agree with your analysis. However I'm hoping that having sourced a chunk of grant funding to pilot test some may be able to do it again on the back of early success/supply contracts or at least some low interest government program. Just wishful thinking. I'm in low so happy to bottom draw it for 12 months if the fund needs to hang on to cash.

Thanks for the clarification.

Where do you get your sales growth from Steph? I have pulled the accounts for a few and have only seen that in some non core, but then again the accounts look back to 23 year ends so would be not the most up to date position. I would like to understand it relative to the size of the investment so I know this is not cherry picking unrepresentative numbers. Did they claim 50% revenue increase last year as well?

I hope you are right Steph. I would have thought any high growth companies in the mix would have been more proactive promoting their ongoing success story and only be reliant on the vc investors to confirm and embellish.

I have seen plenty hammered again after predicting and then disclosing poor results, so have sold 2/3 at a small profit and will either average up if or buyback lower depending on the market reaction. I expect Redwood will mop up so any drop will be just presenting a short term opportunity.

The company treats retail investors as clueless, unlike the detail fed to the likes of Blackrock. Other funds show current equity holdings even if they don't detail the valuation methodology which would be freely provided to auditors. I have a trawl through WIPO to have a better idea of who is developing and protecting their IP and also the volume of hiring, noting almost all the Molton's links fail. Sadly Graphcore is the standout IP with numerous patents filed years ago granted in the past few weeks. Also unless there is growth with limited or no hiring which I guess is slightly possible , unless you happen to be Revolut not much seems to be happening in that space either. So maybe values are still a bit over Cooke.